Strand Therapeutics Appoints Former Nimbus CEO Jeb Keiper to Board as Company Advances Programmable mRNA Platform
Key Insights
Strand Therapeutics (search) has appointed former Nimbus Therapeutics (search) CEO Jeb Keiper as an independent board director to strengthen business development capabilities as the company scales its programmable mRNA platform.
Keiper brings extensive biotech leadership experience, having overseen four clinical programs at Nimbus, raised over $650 million in funding, and executed deals worth over $7 billion during his tenure.
The appointment follows Strand's strong 2025 momentum, including a $153 million Series B financing and positive Phase 1 data for lead candidate STX-001 showing clinical responses in advanced solid tumor patients.
Strand Therapeutics (search) announced the appointment of former Nimbus Therapeutics (search) CEO Jeb Keiper as an independent board director, marking a strategic move to strengthen the company's business development capabilities as it advances its programmable mRNA platform. The Boston-based biotech company is positioning itself for continued growth following a year of significant clinical and financial milestones.
Proven Leadership Experience
Keiper brings over a decade of biotech leadership experience from his tenure at Nimbus Therapeutics (search), where he served in multiple executive roles including Chief Business Officer, Chief Financial Officer, and ultimately CEO. During his leadership, he oversaw the discovery and development of four programs into clinical testing across various indications, raised over $650 million in equity funding, executed deals worth over $7 billion, and returned over $4.1 billion in gains to equity holders.
"We're building the infrastructure of programmable genetic medicines, and bringing Jeb on at this stage reflects the trajectory we're on," said Jake Becraft, PhD, Co-founder and Chief Executive Officer of Strand Therapeutics (search). "He's built multi-billion dollar platform biotechs, structured transformative partnerships, and navigated complex growth stages. That strategic perspective will be invaluable as we scale our platform and advance multiple clinical programs."
Prior to Nimbus, Keiper spent nearly ten years at GSK in various business development leadership roles. He currently serves on the boards of Cardurion Pharmaceuticals and Life Science Cares in Boston.
Clinical Progress and Platform Potential
Keiper expressed enthusiasm about Strand's programmable mRNA technology and its clinical achievements. "Strand's vision to use the demonstrated power of mRNA with precisely programmed expression to any specific cell type has the potential to be transformative for the treatment of many diseases," he said. "Strand has already shown patient success with its first clinical program STX-001, with even more advanced programs coming to the clinic next year and beyond."
The company's lead pipeline program, STX-001, is currently in clinical trials showing what the company describes as unprecedented response rates in late-stage "salvage" cancer (search) patients, with multiple patients demonstrating RECIST responses. These are patients with advanced solid tumors (search) who had exhausted other treatment options.
Strong 2025 Momentum
The board appointment continues Strand's significant momentum throughout 2025. In August, the company closed a $153 million Series B financing led by Kinnevik (search) with participation from multiple large pharmaceutical investors. The company also presented first-in-human Phase 1 data at the 2025 ASCO Annual Meeting, demonstrating multiple clinical responses in patients with advanced solid tumors (search).
With ongoing clinical trials in solid tumors (search) and another trial launching in mid-2026, Strand is demonstrating the breadth and versatility of its platform. The company is also rapidly expanding into CAR-T therapy, showcasing the potential applications of its programmable mRNA technology.
Platform Technology and Future Vision
Strand Therapeutics (search) differentiates itself from traditional mRNA companies through its programmable approach. The company's platform programs RNA to enable logic-controlled expression, precision delivery, and what it describes as unprecedented control over therapeutic outcomes. Unlike conventional mRNA technologies, Strand's system is designed to respond to disease signals in real-time.
The company's technology combines synthetic biology with programmable biology, utilizing a computationally-driven design engine, self-amplifying/circular RNA modalities, and mRNA-only genetic circuits. This approach positions the platform to potentially disrupt multiple therapeutic areas including immuno-oncology, cell therapy, and autoimmune diseases (search).
Leadership Expansion
In early November 2025, Strand announced additional leadership appointments, promoting Prashant Nambiar, MBA, PhD, as Chief Scientific Officer and appointing Ethan Cash as Senior Vice President of Program Management and Strategy. These appointments, along with Keiper's board position, are designed to position Strand to achieve anticipated milestones and advance its mission of integrating genetic medicines into modern therapeutics.
The company describes its modular platform as opening broad opportunities for partnerships and licensing arrangements, positioning itself as what it calls "the operating system for the programmable medicines of tomorrow."